AB-205 is under clinical development by Angiocrine Bioscience and currently in Phase III for Non-Hodgkin Lymphoma. According to GlobalData, Phase III drugs for Non-Hodgkin Lymphoma have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AB-205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-205 is under development for the treatment of Hodgkin and non-Hodgkin lymphoma. It comprises of engineered human umbilical vein endothelial cells administered intravenously. The drug candidate is developed based on E-CEL Technology. The technology utilizes VeraVec endothelial cells genetically modified by insertion of the adenovirus E4ORF1 gene and growth factors to stem cells.
Angiocrine Bioscience overview
Angiocrine Bioscience (Angiocrine) is a cellular therapy company that develops novel treatments based on its proprietary E-CEL technology platform. The company’s pipeline products include E-CEL PEC, E-CEL TEC and E-CEL UVEC. Its E-CEL technology comprises of stem cells and vascular cultured endothelial cells genetically modified by the insertion of the adenovirus E4ORF1 gene. Angiocrine’s E-CEL PEC is used for the treatment of moderate to severe COPD and other lung diseases. The company’s E-CEL UVEC is used for the treatment of high-risk hematologic malignancy and sickle cell diseases. It partners with pharmaceutical and biotechnology companies for its novel drug development. Angiocrine is headquartered in San Diego, California, the US.
For a complete picture of AB-205’s drug-specific PTSR and LoA scores, buy the report here.